Your browser doesn't support javascript.
loading
Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee, Ju Yup; Kim, Nayoung; Park, Kyung Sik; Kim, Hyun Jin; Park, Seon Mee; Baik, Gwang Ho; Shim, Ki-Nam; Oh, Jung Hwan; Choi, Suck Chei; Kim, Sung Eun; Kim, Won Hee; Park, Seon-Young; Kim, Gwang Ha; Lee, Bong Eun; Jo, Yunju; Hong, Su Jin.
Afiliação
  • Lee JY; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Kim N; Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
  • Park KS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. nayoungkim49@empas.com.
  • Kim HJ; Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
  • Park SM; Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Gyeongsangnam-do, South Korea.
  • Baik GH; Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, South Korea.
  • Shim KN; Department of Internal Medicine, Hallym University College of Medicine, Chuncheon Sacred Heart Hospital, Chuncheon, South Korea.
  • Oh JH; Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea.
  • Choi SC; Departments of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Kim SE; Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, South Korea.
  • Kim WH; Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea.
  • Park SY; Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.
  • Kim GH; Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.
  • Lee BE; Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
  • Jo Y; Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
  • Hong SJ; Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, South Korea.
BMC Gastroenterol ; 16(1): 79, 2016 Jul 26.
Article em En | MEDLINE | ID: mdl-27460100
ABSTRACT

BACKGROUND:

The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth quadruple protocol as first-line H. pylori treatment was compared with 10-day sequential therapy.

METHODS:

In total, 390 H. pylori-infected subjects participated in the randomized clinical trial 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days) or 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day). (13)C-urea breath test, rapid urease testing, or histology was performed to check for eradication.

RESULTS:

Intention-to-treat (ITT) eradication rates of 10-day sequential and 14-day quadruple therapy were 74.6 % and 68.7 %, respectively, and the per-protocol (PP) rates were 84.2 and 76.5 %, respectively. The eradication rate was higher in the sequential therapy group, but neither the ITT nor the PP analyses had a significant difference (P = 0.240 and P = 0.099, respectively). However, the adverse events were significantly lower in the modified bismuth quadruple therapy group than the sequential therapy group (36.9 vs. 47.7 %, P = 0.040).

CONCLUSIONS:

Ten-day sequential therapy appears to be more effective despite frequent adverse events. However, both 10-day SQT and 14-day PBAT did not reach the excellent eradication rates that exceed 90 %. Additional trials are needed to identify a more satisfactory first-line eradication therapy. TRIAL REGISTRATION ClinicalTrials.gov ( NCT02159976 ); Registration date 2014-06-03, CRIS ( KCT0001176 ); Registration date 2014-07-23.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tetraciclina / Bismuto / Helicobacter pylori / Infecções por Helicobacter / Gastrite / Amoxicilina / Antiácidos / Antibacterianos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tetraciclina / Bismuto / Helicobacter pylori / Infecções por Helicobacter / Gastrite / Amoxicilina / Antiácidos / Antibacterianos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article